Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Continuous Glucose Monitoring Market $8.5 Billion by 2027

The global market for continuous glucose monitoring devices estimated to reach $8.5 billion by 2027, expanding at a CAGR of 17.8% over the forecast period, driven by growing aging population, diabetes population and pressure to cut the rising healthcare costs.

Global Continuous Glucose Monitoring Market
  • According to American Diabetes Association (2015), 30.3 million Americans, or 9.4% of the population, had diabetes, and 1.5 million Americans are diagnosed with diabetes every year.
    • About 193,000 Americans under age 20 are estimated to have diagnosed diabetes, approximately 0.24% of that population.
  • As per the WHO statistics (WHO Global report on diabetes), the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014.
    • Diabetes prevalence has been rising more rapidly in middle- and low-income countries. Prevalence of type 1 diabetes (T1D) disease is increasing worldwide. In 2016, an estimated 1.6 million deaths were directly caused by diabetes.

Continuous glucose monitoring (CGM) is a small wearable device that tracks blood glucose throughout the day and night, notifying the highs and lows in order to take better treatment decisions and better glucose control. CGM helps to minimize the guesswork that comes from making decisions based solely on a number from a blood glucose meter reading, for better diabetes management.

  • The CGM devices can be used by both type 1 and type 2 diabetics, although they are primarily used by type 1 diabetics due to the critical need for tight glucose control, or by younger users to reduce A1C without increasing hypoglycemia, or those suffer from frequent lows and potentially dangerous nighttime hypoglycemia.
    • The CGM systems improve diabetes treatment and glucose control primarily for people with type 1 diabetes (although, some type 2 diabetic patients with frequent hypoglycemia are also eligible). Additionally, standalone CGMs (when used alone regardless of insulin delivery method including insulin pumps) have the capability to result in significant A1C reductions.
      • Self-monitoring of glucose for individuals afflicted with diabetes mellitus has allowed patients to take control of their disease and thus directly affect the outcomes related to it. 
      • For point-of-care purposes, the CGM devices are considered to be the best candidates for diabetes therapy, and are considered to be the ideal candidate for the next generation products to replace the currently used portable glucose meters.
        • However, the current gold standard glucose biosensors are invasive, and CGM systems still present a number of limitations, such as biofouling, fibrous encapsulation of the implanted electrode, inflammation, and loss of host vasculature, which seriously affect the precision and accuracy of the blood glucose results.
          • Non-invasive methods, on the other hand, are increasingly prevalent due to the highly sensitivity and better patient compliance contrary to invasive ones
Continuous Glucose Monitoring (CGM) Market

The global continuous glucose monitoring market report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027). 

The global market for continuous glucose monitoring devices segmented by product (Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System), and geography.

Leading competitors in the CGM systems segment include Abbott Laboratories (FreeStyle Libre Pro/Flash); Dexcom (G5 Mobile); and Medtronic (iPro/Enlite sensor used with the MiniMed insulin pump, and Guardian Connect mobile CGM). However, several new competing systems are under development, from companies such as Nemaura Medical (sugarBEAT), Senseonics/Roche (Eversense), and others.

  • Medtronic’s first and only US Food and Drug Administration approved hybrid closed-loop system developed in partnership with Tidepool Loop, an open-source iPhone and Apple Watch app, to enter the US market competition soon.
  • Recently, Swiss-based Ascensia signed a distribution and joint-product development deal with Chinese-based diabetes company Zhejiang POCTech Co. Ltd. Under the agreement, Ascensia, which markets the Contour portfolio of blood glucose monitoring systems, will become the exclusive distributor for POCTech CGM devices in an initial 13 specifically selected markets.
  • Similarly, US FDA approved Senseonics’ PMA for Eversense, a subcutaneous CGM system for the US market. Senseonics is signing of a few key deals with third-party payers, including Horizon Blue Cross Blue Shield and Horizon Healthcare.
  • Dexcom Inc., received US FDA nod of its next-generation Dexcom G6 integrated continuous-glucose monitoring (iCGM) system, which does not require calibration by the user during its 10-day use period.

The global continuous glucose monitoring devices market research report is divided by geography (regional and country based) into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

The global CGM systems market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

  • Continuous glucose monitoring product manufacturers holding majority of the market share include Dexcom, Inc., Abbott Laboratories, and Medtronic plc. The upcoming innovative product companies include UK-based Nemaura Medical and US-based Senseonics, Inc.
    • Abbott – FreeStyle Libre, FreeStyle Libre Flash, FreeStyle Libre Pro, FreeStyle Libre 2
    • Dexcom – Dexcom G5 CGM, Dexcom G6 CGM
    • Medtronic – Guardian Connect CGM, iPro2 professional
    • Nemaura Medical – SugarBEAT
    • Senseonics – Eversense CGM System, Eversense XL CGM System

Major competitors operating in the global market for continuous glucose monitoring products and included in this report are Abbott Laboratories, Inc., Bayer AG, Dexcom, Inc., GlySens, Inc., Insulet Corp., Medtronic, Inc., Nemaura Medical, Nova Biomedical Corporation, and Senseonics Holdings, Inc.

  • Product
    • Dexcom G4 Platinum
    • Dexcom Seven Plus CGM System
    • FreeStyle Navigator
    • Guardian Real Time CGM System
    • MiniMed Paradigm Revel/Veo System
    • Other Products
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Bayer AG
    • Dexcom, Inc.
    • GlySens, Inc.
    • Insulet Corporation
    • Medtronic plc
    • Nemaura Medical
    • Nova Biomedical Corporation
    • Senseonics Holdings, Inc.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]